Seamless Therapeutics and Eli Lilly Forge ~$1.12B Deal to Develop Hearing Loss Therapies

Shots:

• Seamless has entered into a strategic global research collaboration & licensing deal with Eli Lilly to develop & commercialize programmable recombinase-based therapies for hearing loss using Seamless’ proprietary recombinase platform
• Under the deal, Seamless will design site-specific recombinases to correct hearing-loss–related gene mutations, while Lilly will receive an exclusive license to advance these programmed recombinases through preclinical, clinical development & commercialization
• As per the deal, Seamless will receive an upfront & R&D funding, with over ~$1.12B in development & commercial milestones, plus tiered royalties; further details remain undisclosed

Ref: Seamless |   Image: Seamless & Eli Lilly | Press Release

Related News: Eli Lilly Reports P-IIIb (TOGETHER-PsA) Trial on Taltz + Zepbound for Psoriatic Arthritis and Obesity or Overweight

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com